Dan Moore has been a strategic communications advisor for nearly two decades, during which time he has counseled hundreds of companies around proxy fights, transactions and restructurings, as well as ongoing reputation management, investor and media relations.
Select mandates over the years include Box in its proxy fight win against Starboard Value, 3M in its separation of its healthcare business, Teva Pharmaceuticals in its unsolicited proposal to acquire Mylan and in its acq. of Allergan Generics, among many other event-driven and crisis assignments. Dan thrives in the intense, high-profile situations that change the fabric of companies and their leadership teams.
He started his career at FTI Consulting in the special situations and strategy consulting practices. He is a member of the National Investor Relations Institute (NIRI) and was named to NIRI’s Rising Leaders Under 40. He was a partner at Joele Frank until 2023.
- USA Rare Earth in its $2.8B acquisition of Serra Verde
- Marelli in its Chapter 11 restructuring
- Chimerix ($935 million sale to Jazz Pharmaceuticals)
- Alumis (stock for stock merger with ACELYRIN)
- Resideo (separation of ADI Business from P&S Business)
- MDC Holdings ($4.9 billion sale to Sekisui House Ltd.)
- Admiral Acquisition ($1.85 billion acquisition of ASP Acuren Holdings)
- MRC Global ($1.5 billion all-stock acquisition by DNOW)
- APi Group ($570 million acquisition of Elevated Facility Services Group)
- Vanda Pharmaceuticals (defense of an unsolicited acquisition proposal)
- Box (Starboard)
- Cerner (Starboard Value)
- Chico’s (Barington)
- Dynavax (Deep Track Capital)
- Hertz (Carl Icahn)
- Matthews International (Barington Capital)
- Mercury Systems (Jana Partners, Starboard Value)
- MRC Global (Engine Capital)
- Monotype (Starboard Value)
- True Blue (EHS Investments)